Welcome to our dedicated page for Poseida Therapeutics news (Ticker: PSTX), a resource for investors and traders seeking the latest updates and insights on Poseida Therapeutics stock.
Poseida Therapeutics, Inc. (NASDAQ: PSTX) is a clinical-stage biopharma leader developing non-viral allogeneic cell therapies and genetic medicines. This news hub provides investors and researchers with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Access verified information about PSTX's CAR-T programs, gene editing innovations, and manufacturing advancements. Our curated collection includes press releases on clinical data readouts, FDA designations, collaboration expansions with partners like Roche, and financial performance updates.
Key content categories cover therapy development progress across oncology and rare diseases, technology platform enhancements, and business development activities. Bookmark this page for timely updates on Poseida's pioneering work in TSCM-rich cell therapies and its growing pipeline of precision genetic medicines.
Poseida Therapeutics (Nasdaq: PSTX) announced the appointment of Rafael G. Amado, M.D., to its Board of Directors on April 13, 2023. Dr. Amado brings extensive expertise in oncology and cell therapies, supporting Poseida's mission to advance innovative treatments for cancer and rare diseases. His leadership roles at Zai Lab, Allogene Therapeutics, and Adaptimmune, along with his background in pharmaceutical research, position him well to provide strategic insights. The CEO, Mark Gergen, welcomed Dr. Amado, emphasizing his potential contribution to the company's growth and the development of its promising pipeline in oncology and genetic diseases. The company focuses on differentiated cell and gene therapies, utilizing proprietary platforms for its product candidates.
On April 11, 2023, Poseida Therapeutics (NASDAQ: PSTX) announced an inducement award for Kristin Yarema, the new President of Cell Therapy. The award consists of a stock option for 498,325 shares priced at the fair market value on the grant date, vesting over four years, and a restricted stock unit for 356,836 shares, also vesting over four years. Yarema's employment is subject to the terms of these agreements. Poseida is focused on developing innovative gene and cell therapies aimed at curing cancers and rare diseases, utilizing proprietary technologies such as the piggyBac® DNA Delivery System and Cas-CLOVER™ Gene Editing. The company has strategic collaborations with Roche and Takeda to further enhance its therapeutic initiatives.
FAQ
What is the current stock price of Poseida Therapeutics (PSTX)?
What is the market cap of Poseida Therapeutics (PSTX)?
